2-Star Stocks Poised to Plunge: Incyte?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Based on the aggregated intelligence of 165,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Incyte (Nasdaq: INCY  ) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Incyte's business and see what CAPS investors are saying about the stock right now.

Incyte facts

Headquarters (Founded)

Wilmington, Del. (1991)

Market Cap

$1.6 billion



Trailing-12-Month Revenue

$25.9 million


CEO Dr. Paul Friedman (since 2001)
CFO David Hastings (since 2003)

Return on Capital (Average, Past 3 Years)


Compound Annual Revenue Growth (Over Past 3 Years)


1-Year Return



Amgen (Nasdaq: AMGN  )
Bristol-Myers Squibb (NYSE: BMY  )

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 10% of the 254 members who have rated Incyte believe the stock will underperform the S&P 500 going forward. These bears include JackCaps and All-Star zzlangerhans, who is ranked in the top 0.5% of our community.

Just last month, JackCaps touched briefly on Incyte's skyrocketing stock price: "Incyte looks poised for a technical retreat."

In an earlier pitch, zzlangerhans also offered some insight into Incyte's risk/reward profile:

Incyte is at an eight year high less than a year after what I believe was a fifteen year low last April. Kudos to anyone who had the foresight ... to buy biotech during the meltdown last spring. But if you invested in Incyte back then, cash out and buy yourself something nice. The pipeline and partnerships have potential, but not 1.5 billion market cap potential at this time. Given the ebb and flow inherent in baby biotech, allow yourself a chance to buy it again below 5 next time the worm turns.

What do you think about Incyte, or any other stock for that matter? If you want to retire rich, you need to protect your portfolio from any undue risk. Staying away from dangerous stocks is crucial to securing your financial future, and on Motley Fool CAPS, thousands of investors are working every day to flag them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool's disclosure policy always gets a perfect score.

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1201575, ~/Articles/ArticleHandler.aspx, 10/26/2016 5:55:09 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
INCY $87.25 Up +0.05 +0.06%
Incyte CAPS Rating: **
AMGN $158.99 Up +1.10 +0.69%
Amgen CAPS Rating: ****
BMY $49.29 Down -0.26 -0.52%
Bristol-Myers Squi… CAPS Rating: ****